Among patients with rheumatoid arthritis, JAK inhibitors were slightly more effective for reducing pain at 3 and 12 months when compared with TNF inhibitors.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA ... that are directed against TNF: infliximab, adalimumab, golimumab ...

Tumour Necrosis Factor TNF is crucial for defence but can drive chronic inflammation linked to arthritis and autoimmune diseases when overproduced ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Alvotech and Advanz Pharma’s ...

Medically reviewed by Elizabeth Barnes, RDN Ginger is a spice that comes from the rhizome (or root) of the flowering plant ...

If you take medications to treat rheumatoid arthritis, smoking can interfere with their activity and make them less effective. This includes such foundational medications as methotrexate and newer TNF ...